Mostrando las entradas con la etiqueta England. Mostrar todas las entradas
Mostrando las entradas con la etiqueta England. Mostrar todas las entradas

31 mayo, 2013

Natural inmunity against A/H1N1 2009 ( flu virus )

English: Swineflu cases in the UK (HPA modelling)
English: Swineflu cases in the UK (HPA modelling) (Photo credit: Wikipedia)

 In spite of many evidence support that the flu vaccine is not effective, this article focus also in the natural inmunity against the A/N1H1, where in cities like London the number climbs to 70% of the population who has natural antibodies against these virus. So, the question is......why the CDC and WHO persist in these kinds of policies, where the only who win something is Big Pharma ?

Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A/H1N1 2009.

Full Text

Source

Centre for Infections, Health Protection Agency, London, UK.

Abstract

OBJECTIVES:

The objectives of the H1N1 2009 serological surveillance project were twofold: to document (1) the prevalence of cross-reactive antibodies to H1N1 2009 by age group in the population of England prior to arrival of the pandemic strain virus in the UK and (2) the age-specific incidence of infection by month as the pandemic progressed by measuring increases in the proportion of individuals with antibodies to H1N1 2009 by age.

METHODS:

Residual aliquots of samples submitted to 16 microbiology laboratories in eight regions in England in defined age groups in 2008 and stored by the Health Protection Agency serological surveillance programme were used to document age-stratified prevalence of antibodies to H1N1 2009 prior to the arrival of the pandemic in the UK. Functional antibodies to the H1N1 2009 virus were measured by haemagglutination inhibition (HI) and microneutralisation (MN) assays. For timely measurement of monthly incidence of infection with H1N1 2009 between August 2009 and April 2010, the microbiology serum collections were supplemented by collection of residual sera from chemical pathology laboratories in England. Monthly seroincidence samples were tested by HI only, apart from the final sera collected post pandemic in 2010, which were also tested by MN. Incidence during the pandemic was estimated from changes in prevalence between time points and also by a likelihood-based method.

SETTING:

Eight regions of England.

PARTICIPANTS:

Serum samples from patients accessing health care in England from whom blood samples were taken for unrelated microbiological or chemical pathology testing.

INTERVENTIONS:

None.

MAIN OUTCOME MEASURES:

Baseline age-specific prevalence of functional antibodies to the H1NI 2009 virus prior to the arrival of the pandemic; changes in antibody prevalence during the period August 2009 to April 2010.

RESULTS:

Pre-existing cross-reactive antibodies to H1N1 2009 were detected in the baseline sera and increased with age, particularly in those born before 1950. The prediction of immunological protection derived from the baseline serological analysis was consistent with the lower clinical attack rates in older age groups. The high levels of susceptibility in children < 15 years, together with their mixing within school, resulted in the highest attack rates in this age group. Serological analysis by region confirms that there were geographical differences in timing of major pandemic waves. London had a big first wave among the 5- to 14-year age group, with the rest of the country reducing the gap after the second wave. Cumulative incidence in London remained higher throughout the pandemic in each age group. By the end of the second wave it is estimated that as many as 70% of school-aged children in London had been infected. Taken together, these observations are consistent with observations from previous pandemics in 1918, 1957 and 1968 - that the major impact of influenza pandemics is on younger age groups, with a pattern of morbidity and mortality distinct from seasonal influenza epidemics.

CONCLUSIONS:

Serological analysis of appropriately structured, age-stratified and geographically representative samples can provide an immense amount of information to set in context other measures of pandemic impact in a population, and provide the most accurate measures of population exposure. National scale seroepidemiology studies require cross-agency coordination, multidisciplinary working, and considerable scientific resource.

FUNDING:

The National Institute for Health Research Health Technology Assessment programme and the Health Protection Agency.
Enhanced by Zemanta

16 mayo, 2013

Global action on social determinants of health


Source: WHO - Global action on social determinants of health

Michael Marmot a

a. Department of Epidemiology and Public Health, University College London, 1–19 Torrington Place, London, WC1E 6BT, England.
Correspondence to Michael Marmot (e-mail: m.marmot@ucl.ac.uk).
Bulletin of the World Health Organization 2011;89:702-702. doi: 10.2471/BLT.11.094862
Closing the gap in a generation is a rousing call.1 Did the World Health Organization’s Commission on Social Determinants of Health (CSDH) really believe it to be possible? Technically, certainly. Yes, there is a greater than 40-year spread in life expectancy among countries and dramatic social gradients in health within countries. But the evidence suggests that we can make great progress towards closing the health gap by improving, as the CSDH put it, the conditions in which people are born, grow, live, work and age. These include ensuring: equity for every child from the start, healthier environments, fair employment and decent work, social protection across the life course and universal health care. To make such progress, we must also deal with inequity in power, money and resources – the social injustice that is killing on a grand scale. At a more fundamental level, our vision is to create the conditions so that every person may enjoy the freedoms that lead to improved health – what we call empowerment.
In the three years since Closing the gap in a generation was published, there is no question that there is much to make us gloomy: the global financial crisis and the steps put in place to deal with it have worse impacts on the poor and relatively disadvantaged; the persistence of bad governance nationally and globally; climate change and inequitable measures for mitigation and adaptation and, in many countries, an increase in health inequity.
On the positive side, however, much has happened to support my claim that I am an evidence-based optimist. First at the World Health Organization (WHO) itself, the doubting voices (what do social determinants have to do with a disease control organization?) were countered by the argument that WHO could not possibly ignore what the CSDH called “the causes of the causes” of ill-health. Specialists across WHO, who formed the CSDH’s knowledge network on priority public health conditions, showed that action on social determinants of health was fundamental to disease control programmes.2 Importantly, a resolution was passed at the World Health Assembly in 2009 that called on WHO and all Member States to take action on the social determinants.
Each of the WHO Regions has expressed interest in this issue. The WHO Regional Office for the Americas will make social determinants a theme for its publication Health in the Americas 2012, has developed training courses and has been promoting health equity in the region. Zsuzsanna Jakab, WHO Regional Director for Europe, thought it essential that work be done to adapt the CSDH findings to the diverse countries that make up the WHO European Region. She therefore invited me to lead the European Review of Social Determinants and the Health Divide. The recommendations from this review will feed in to Europe’s new public health strategy, Health 2020. WHO, with the government of Brazil, is organizing the World Conference on Social Determinants of Health in Rio de Janeiro.
Several countries have explicitly taken on the social determinants of health agenda. Brazil, Denmark, England, Norway, Scotland and Slovenia are among many countries that have commissioned reviews and/or produced strategies for action on this subject. In other countries such as Argentina, Chile, Costa Rica and Sri Lanka, there is much focus on and concern about the social determinants of health and a variety of actions have been taken. The state of South Australia has made the Health in All Policies approach a central plank of government action. India, while not explicitly addressing the social determinants of health has, nevertheless, pursued policy initiatives that will have important impact on health equity. These include: rural employment guarantees, food security, universal health care, social security for informal workers, education, housing and rights of tribal and forest dwellers. These new policies and programmes are all welcome but the proof will come from monitoring their effect on social determinants and health outcomes.
The review of health inequalities in England, published as Fair society, healthy lives,3 adapted the CSDH recommendations into six domains: (i) give every child the best start in life, (ii) improve education and life-long learning, (iii) create fair employment and jobs, (iv) ensure a minimum income for a healthy standard of living, (v) build healthy and sustainable communities, and (vi) apply a social determinants’ approach to prevention. In the wake of this review there are encouraging signs of impact on policy and practice at national and local level in the United Kingdom of Great Britain and Northern Ireland.
The ambition of the CSDH was to create a global movement for social determinants and health equity. As the global community gathers in Rio de Janeiro in October for the conference on social determinants of health, we are at a crucial juncture. Will the call for social justice and the need to formulate all policies to benefit health equity remain something, at best, honoured in speech alone? Or will the global community recognize that action on social determinants of health is not only vital for health equity but has other highly desirable societal outcomes including social cohesion, reduction of crime and civil unrest, a more educated workforce and the freedom for people to lead lives they have reason to value.4


Translate to Chinese 

References

14 mayo, 2013

Time to say goodbye to minocycline?


DTB 51:49 doi:10.1136/dtb.2013.5.0176
  • Articles
Minocycline has been licensed for over 35 years for a wide range of bacterial infections (a Summary of Product Characteristics [SPC] lists 16 indications) including respiratory, genitourinary and skin conditions.1,2 However, much of its popularity has been for its use in treating acne. Minocycline was associated with claims that it was “more effective, less likely to cause bacterial resistance and easier to take than other tetracyclines”.3 In addition, the availability of an adherence-friendly, once-daily, modified-release preparation and a lack of restriction when taken with food or ‘moderate amounts of milk’, quickly made it a favourite with general practitioners and patients. It became particularly popular for use for teenagers with acne, a group notorious for non-adherence and for whom a single daily dose was seen as an advantage. Between 1997 and 2006 about 500,000 prescriptions for minocycline were dispensed each year in England, accounting for about one third of all tetracycline prescriptions by volume and two thirds by cost.4 Partly as a result of concerns over its safety, the amount of minocycline prescribed has fallen by about two thirds, while the overall volume of prescribing of all tetracyclines has increased by 10%. However, given that over 100,000 prescriptions for minocycline are still issued each year, is further action required in light of the adverse effect profile of the drug?
Doubts about the safety of minocycline started in the 1990s with reports of rare but serious and apparently idiosyncratic adverse effects that included hypersensitivity reactions of eosinophilia, pneumonitis and nephritis, autoimmune hepatitis and lupus erythematosus-like syndrome.5,6 Such reactions seem to be more common with minocycline than with other tetracyclines.7 In addition, minocycline appears to be the only tetracycline that can cause potentially irreversible slate-grey pigmentation of the skin.1 The ‘Special warnings and precautions …

29 marzo, 2013

Clinical Knowledge Summaries (CKS)

National Institute for Health and Clinical Exc...
National Institute for Health and Clinical Excellence (Photo credit: Wikipedia)

                         
 In advance of this, we are providing a preview of the new CKS service homepage for your information.
    
This new CKS service will upgrade the existing CKS service and will be openly accessible to users in the UK at
 www.cks.nhs.uk. The service will continue to be aimed at primary care practitioners and will contain over 300 
topics on the most common and/or significant primary care presentations for use preparing for, during and
 following on from patient consultations.
                                                       
The evidence base that supports these topics will be continuously reviewed and significant changes will lead to
 accelerated topic updates. Up to ten new topics will be introduced each year and all topics will be reviewed on a
 four year rolling cycle.
                                                                                                                                                       ;                                                                       
Some of the new topics already planned for release in 2013 are anxiety, postnatal care, and pain and bleeding in
 early pregnancy.
                                                       
 We would also encourage you to register as a NICE user and benefit from all the services offered by NICE.
 Please click on this link and complete the registration details.
                                                       
 You can also register for a My Evidence account by clicking on this link.
                                                                                                               
We will be providing more information about the new and improved CKS service from NICE over the coming
 weeks.

Clinical Knowledge Summaries (CKS) service commissioned by the National Institute for Health and Clinical Excellence (NICE) will be going live on 8 April 2013.                              
Enhanced by Zemanta